Maxygen MAXY
-
Maxygen : Bayer $30 Million Payment Likely In 2012
… previously written on why I think that Maxygen , Inc. ( MAXY ) is an attractive long with minimal ..... 00 per share higher. Review of MAXY investment thesis First, I'll review the investment thesis on Maxygen . MAXY is Complete Story »
-
Maxygen : A Biotech Play With Low Downside - Part 2
… our two-part series on Maxygen ( MAXY ), we discussed the company ..... second source of value is Maxygen 's MAXY G34 drug, the "bio-better ..... 4.8 billion in 2010. MAXY G34 is the most difficult of Maxygen 's assets to value, given …
-
Maxygen : A Biotech Play With Low Downside - Part 1
… shareholders. We think Maxygen ( MAXY ) is one such stock that ..... first part discusses Maxygen 's history, the company ..... gone public in 1999, Maxygen was unable to develop ..... through the sale process, MAXY 's board Complete Story …
-
Prolor Biotech: De-Risked And Ready To Begin Phase 3 Trials
By Steven Breazzano : Upcoming Events - Initiation of Phase 3 in adults (2012), and Phase 2 in children (Q4 2011 – Q1 2012). Prolor Biotech ( PBTH ) – based in Nes-Ziona, Israel engages in the development and commercialization of bio-better proteins and peptides. Utilizing their proprietary CTP ...
-
Maxygen ( MAXY ) gains in the post-session after it says the U.S. Patent and Trademark Office has rejected all of Amgen's (AMGN) patent claims to certain molecules that potentially cover Maxygen's ...
Maxygen ( MAXY ) gains in the post-session after it says the U.S. Patent and Trademark Office has rejected all of Amgen's ( AMGN ) patent claims to certain molecules that potentially cover Maxygen 's MAXY -G34 drug candidate. MAXY +3.2% AH. Post your comment!
-
Dropping Coverage of Maxygen
We are no longer providing equity research on Maxygen MAXY . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
-
Maxygen Undergoes Reorganization
… estimate after evaluating Maxygen 's MAXY recent corporate reorganization ..... a prior partnership, Maxygen and Astellas Pharma have ..... including the firm's MAXY -4 program and other ..... option to acquire all of Maxygen 's ownership interest …
-
Maxygen's Pipeline Still on Hold
… value estimate after reviewing Maxygen 's MAXY progress in 2008. Although fourth ..... cutting costs, we are concerned that Maxygen is locked in a stalemate: The ..... more information on the future of Maxygen 's clinical lineup before raising …
-
Maxygen Still Hoping for Partner
… month, we are keeping an eye on Maxygen 's MAXY success in executing last fall ..... partnership opportunities, Maxygen is also contemplating the sale ..... or the whole company itself. Maxy -G34 is now Maxygen 's only wholly owned drug …
-
Maxygen Strikes Deal with Astellas
After reviewing Maxygen 's MAXY most recent financial results ..... battle with Amgen AMGN. Maxygen also recently announced ..... to develop and market its Maxy -4 autoimmune disease drug candidates, and Maxygen received an up-front payment …